An observational study in Intracranial Aneurysm, sponsored by Microvention-Terumo, Inc.. Completed at 1 site in France. Per ClinicalTrials.gov, last updated 2024-01-23.
Sponsored by Microvention-Terumo, Inc. · Observational
A French, multicenter, prospective, observational, "real-world" assessment of the safety and efficacy of FRED and FRED Jr devices in the treatment of intracranial aneurysms
Post Market Clinical Follow-up. Multicenter observational study. Treatment and follow-up far at least 12 months as per standard of care.
Sample Size: 138 patients.
427 studies on the registry are indexed under Intracranial Aneurysm; 115 are open to participants now.
This study's enrollment of 135 is below the median of 200 across 198 observational studies indexed under Intracranial Aneurysm.
Browse Intracranial Aneurysm studies →Microvention-Terumo, Inc. is the lead sponsor of 32 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patient with an intracranial aneurysm treated with the FRED or FRED JR Device
Exclusion Criteria:
Intracranial aneurysm treatment
Also known as: Flow Re-Direction Endoluminal Device
Mortality Rate
Percentage of patients with neurological death
Time frame: 1 year
Morbidity Rate
Percentage of patients with major ipsilateral stroke
Time frame: 1 year
modified Rankin Score
worsening mRS (scale from 0 to 6 : 0= No symptom, 6= Death)
Time frame: 1 year
Complete aneurysm occlusion rate
Measured by the Raymond Scale
Time frame: 1 year
Retreatment Rate
Rate and description of aneurysm retreated or planned for retreatment
Time frame: 1 year
Patient description
Description of the population of patients treated with FRED and FRED JR in France
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Microvention-Terumo, Inc.